Prevalence and characteristics of allodynia in headache sufferers: a population study

M E Bigal, S Ashina, R Burstein, M L Reed, D Buse, D Serrano, R B Lipton, AMPP Group, Richard B Lipton, Marcelo E Bigal, Dawn Buse, Michael L Reed, Walter Stewart, Merle Diamond, Frederick Freitag, Elisabeth Hazard, Jonothan Tierce, Elizabeth Loder, Paul Winner, Stephen Silberstein, Suzanne Simons, Seymour Diamond, M E Bigal, S Ashina, R Burstein, M L Reed, D Buse, D Serrano, R B Lipton, AMPP Group, Richard B Lipton, Marcelo E Bigal, Dawn Buse, Michael L Reed, Walter Stewart, Merle Diamond, Frederick Freitag, Elisabeth Hazard, Jonothan Tierce, Elizabeth Loder, Paul Winner, Stephen Silberstein, Suzanne Simons, Seymour Diamond

Abstract

Objective: The authors estimated the prevalence and severity of cutaneous allodynia (CA) in individuals with primary headaches from the general population.

Methods: We mailed questionnaires to a random sample of 24,000 headache sufferers previously identified from the population. The questionnaire included the validated Allodynia Symptom Checklist (ASC) as well as measures of headache features, disability, and comorbidities. We modeled allodynia as an outcome using headache diagnosis, frequency and severity of headaches, and disability as predictor variables in logistic regression. Covariates included demographic variables, comorbidities, use of preventive medication, and use of opioids.

Results: Complete surveys were returned by 16,573 individuals. The prevalence of CA of any severity (ASC score >or=3) varied with headache type. Prevalence was significantly higher in transformed migraine (TM, 68.3%) than in episodic migraine (63.2%, p < 0.01) and significantly elevated in both of these groups compared with probable migraine (42.6%), other chronic daily headaches (36.8%), and severe episodic tension-type headache (36.7%). The prevalence of severe CA (ASC score >or=9) was also highest in TM (28.5%) followed by migraine (20.4%), probable migraine (12.3%), other chronic daily headaches (6.2%), and severe episodic tension-type headache (5.1%). In the migraine and TM groups, prevalence of CA was higher in women and increased with disability score. Among migraineurs, CA increased with headache frequency and body mass index. In all groups, ASC scores were higher in individuals with major depression.

Conclusions: Cutaneous allodynia (CA) is more common and more severe in transformed migraine and migraine than in other primary headaches. Among migraineurs, CA is associated with female sex, headache frequency, increased body mass index, disability, and depression.

Figures

Figure 1
Figure 1
Relative frequency and severity of cutaneous allodynia according to headache subtype CA = cutaneous allodynia; TM = transformed migraine; M = migraine; PM = probable migraine; O-CDH = other chronic daily headaches; ETTH = episodic tension-type headache.
Figure 2
Figure 2
Mean allodynia symptom checklist score, overall and by gender, in individuals with primary headache disorders TM = transformed migraine; PM = probable migraine; O-CDH = other chronic daily headaches; S-ETTH = severe episodic tension-type headache.

References

    1. Woolf CJ, Wall PD. Relative effectiveness of C primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat. J Neurosci. 1986;6:1433–1442.
    1. Sivilotti L, Woolf CJ. The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol. 1994;72:169–179.
    1. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703–1709.
    1. Sessle BJ, Hu JW, Amano N, Zhong G. Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain. 1986;27:219–235.
    1. Wolff HG, Tunis MM, Goodell H. Studies on migraine. Arch Intern Med. 1953;92:478–484.
    1. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23:23–32.
    1. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614–624.
    1. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26.
    1. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334–1343.
    1. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interic-tally using a questionnaire? Neurology. 2005;65:1419–1422.
    1. Lipton RB, Bigal ME, Burstein R, et al. Cutaneous allodynia in the migraine population. Ann Neurol Epub. 2007 Dec 4;
    1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349.
    1. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache. 2007;47:355–363.
    1. Headache Classification Subcommittee of the International Headache Society . Cephalgia. suppl 1. ed 2 Vol. 24. 2004. The International Classification of Headache Disorders; pp. 1–15.
    1. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871–875.
    1. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–645.
    1. Liebestein M, Bigal ME, Sheftell FD, et al. Validation of the chronic daily headache questionnaire. Neurology. 2007;68(suppl 1):369.
    1. Stewart WF, Lipton RB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41–52.
    1. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA. 1994;272:1749–1756.
    1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657.
    1. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:87–96.
    1. Bigal ME, Sheftell FD, Rapoport AM, et al. Chronic migraine is the early stage of transformed migraine in adults. Neurology. 2005;65:1556–1561.
    1. Samejima F. Estimating latent ability using a pattern of graded scores. The William Byrd Press; Richmond, VA: 1969. p. 14. (Psychometrika Monograph Supplement, No. 17).
    1. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493–494.
    1. Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother. 2006;6:297–306.
    1. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89.
    1. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334–1343.
    1. Poceta JS, Dalessio DJ. Identification and treatment of sleep apnea in patients with chronic headache. Headache. 1995;35:586–589.
    1. Bigal ME, Lieberman JN, Lipton RB. Obesity and migraine. A population study. Neurology. 2006;66:545–550.
    1. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001;357:1016–1017.
    1. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159–177.
    1. Hoheisel U, Mense S. Long-term changes in discharge behavior of cat dorsal horn neurones following noxious stimulation of deep tissues. Pain. 1989;36:239–247.
    1. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964–982.
    1. Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629–637.
    1. Gazerani P, Andersen OK, Arendt-Nielsen L. A human experimental capsaicin model for trigeminal sensitization: gender-specific differences. Pain. 2005;118:155–163.
    1. Sekine Y, Suzuki K, Ramachandran PV, Blackburn TP, Ashby CR., Jr Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse. 2007;61:72–77.
    1. Matharu MS, Goadsby PJ. Functional brain imaging in hemicrania continua: implications for nosology and pathophysiology. Curr Pain Headache Rep. 2005;9:281–288.
    1. Herishanu Y, Rogowski O, Polliack A, Marilus R. Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol. 2006;76:516–520.
    1. Zelissen PM, Koppeschaar HP, Lips CJ, Hackeng WH. Calcitonin gene-related peptide in human obesity. Peptides. 1991;12:861–863.
    1. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67:246–251.
    1. Hasselbalch SG, Madsen K, Svarer C, et al. Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol Aging Epub. 2007 Jun 1;
    1. Togsverd M, Werge TM, Tanko LB, et al. Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J Affect Disord Epub. 2007 Aug 13;
    1. Gesztelyi G, Bereczki D. Disability is the major determinant of the severity of depressive symptoms in primary headaches but not in low back pain. Cephalalgia. 2005;25:598–604.
    1. Dando WE, Branch MA, Maye JP. Headache disability in orofacial pain patients. Headache. 2006;46:322–326.
    1. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–342.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi